Anatara Lifesciences (ASX:ANR) has updated investors on an analysis following the completion of Stage 2 of its GaRP-IBS (Irritable Bowel Syndrome) trial.
Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial
April 22, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 5 September
September 5, 2025 - - Podcast -
Novartis ANZ appoints Marco Muscardo as ad-interim Country PresidentÂ
September 4, 2025 - - Latest News -
Australian industry looks to the UK as likely lesson for US 'Most Favored Nation'
September 4, 2025 - - Latest News -
Every new working group and every consultation squeezes more life out of reform, like a lemon wrung to its rind
September 4, 2025 - - Latest News -
The latest HTA Review report is a Dickensian tribute to policymaking and reform
September 3, 2025 - - Latest News -
Stakeholders could be mistaken for thinking the process is the point
September 3, 2025 - - Latest News -
Regulate the regulators - Why NDIS audit fees are failing providers and participants
September 3, 2025 - - Latest News